Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $189,297 - $232,308
8,100 New
8,100 $224,000
Q4 2022

Feb 14, 2023

SELL
$21.94 - $26.24 $94,342 - $112,832
-4,300 Reduced 22.16%
15,100 $394,000
Q3 2022

Nov 14, 2022

BUY
$22.0 - $31.87 $426,800 - $618,278
19,400 New
19,400 $433,000
Q4 2018

Feb 14, 2019

SELL
$27.94 - $44.61 $620,268 - $990,342
-22,200 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$38.6 - $46.12 $463,200 - $553,440
-12,000 Reduced 35.09%
22,200 $942,000
Q2 2018

Aug 14, 2018

BUY
$40.56 - $51.36 $1.39 Million - $1.76 Million
34,200 New
34,200 $1.41 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.8B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.